APA (7th ed.) Citation

Stahl, M., Roehmel, J., Eichinger, M., Doellinger, F., Naehrlich, L., Kopp, M., . . . Mall, M. (2021). WS12.1 An exploratory study to determine the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in children 2 through 5 years of age with cystic fibrosis homozygous for F508del-CFTR (F/F). Journal of Cystic Fibrosis, 20, S22. https://doi.org/10.1016/S1569-1993(21)00981-4

Chicago Style (17th ed.) Citation

Stahl, M., et al. "WS12.1 An Exploratory Study to Determine the Impact of Lumacaftor/ivacaftor (LUM/IVA) on Disease Progression in Children 2 Through 5 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR (F/F)." Journal of Cystic Fibrosis 20 (2021): S22. https://doi.org/10.1016/S1569-1993(21)00981-4.

MLA (9th ed.) Citation

Stahl, M., et al. "WS12.1 An Exploratory Study to Determine the Impact of Lumacaftor/ivacaftor (LUM/IVA) on Disease Progression in Children 2 Through 5 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR (F/F)." Journal of Cystic Fibrosis, vol. 20, 2021, p. S22, https://doi.org/10.1016/S1569-1993(21)00981-4.